Explore

Reuters Reuters
Novo outlook hike falls flat as high Wegovy pill hopes unmet

Novo outlook hike falls flat as high Wegovy pill hopes unmet

By Stine Jacobsen and Maggie Fick COPENHAGEN, Aug 4 (Reuters) - Novo Nordisk beat second-quarter profit forecasts and raised its full-year outlook on Wednesday, but shares in the drugmaker fell 6% as investors focused on underwhelming sales of its Wegovy weight-loss pill.
Reuters Reuters
Novo outlook hike falls flat as Wegovy pill sales fail to impress

Novo outlook hike falls flat as Wegovy pill sales fail to impress

By Stine Jacobsen, Maggie Fick and Bhanvi Satija COPENHAGEN, Aug 4 (Reuters) - Novo Nordisk raised its full-year profit and sales outlook on Tuesday but disappointed investors who focused instead on a narrow sales miss for its new Wegovy pill and a trial setback for its next-generation obesity drug
Reuters Reuters
Eli Lilly raises annual revenue forecast as GLP-1 drugs fuel growth

Eli Lilly raises annual revenue forecast as GLP-1 drugs fuel growth

Aug 5 (Reuters) - Eli Lilly and Co posted better-than-expected quarterly results and raised its full-year revenue forecast on Wednesday, banking on sustained demand for its blockbuster GLP-1 weight-loss and diabetes drugs, sending its shares up 5% in premarket trading.
Trendline Trendline
SB1 Markets Recommends Buying Novo Nordisk Stock Ahead of Earnings Report

SB1 Markets Recommends Buying Novo Nordisk Stock Ahead of Earnings Report

SB1 Markets Recommends Buying Novo Nordisk Stock Ahead of Earnings Report
Trendline Trendline
Novo Nordisk Shares Decline After Disappointing Guidance

Novo Nordisk Shares Decline After Disappointing Guidance

Novo Nordisk Shares Decline After Disappointing Guidance
Reuters Reuters
Lilly's Mounjaro, Zepbound sales surge, widening lead over Novo Nordisk

Lilly's Mounjaro, Zepbound sales surge, widening lead over Novo Nordisk

By Mrinalika Roy and Mariam Sunny Aug 5 (Reuters) - Sales of Eli Lilly's Zepbound and Mounjaro injectable weight-loss and diabetes drugs soared during the second quarter, easily beating Wall Street estimates and widening the gap with Danish rival Novo Nordisk.
Reuters Reuters
CVS profit outlook overshadows strong quarter, shares fall

CVS profit outlook overshadows strong quarter, shares fall

By Amina Niasse and Christy Santhosh NEW YORK, Aug 5 (Reuters) - CVS Health reported better-than-expected second-quarter results on Wednesday, but its updated 2026 forecast and 2027 profit outlook appeared to underwhelm some investors, and its shares fell nearly 6%.
Trendline Trendline
Novo Nordisk Stock Falls Despite Upgraded Financial Forecast

Novo Nordisk Stock Falls Despite Upgraded Financial Forecast

Novo Nordisk Stock Falls Despite Upgraded Financial Forecast
Trendline Trendline
Merck Reports Q2 2026 Financial Results, Highlights Key Drug Approvals

Merck Reports Q2 2026 Financial Results, Highlights Key Drug Approvals

Merck Reports Q2 2026 Financial Results, Highlights Key Drug Approvals
Reuters Reuters
Analysis-Obesity battle heats up again as Novo claws way back into race with Lilly

Analysis-Obesity battle heats up again as Novo claws way back into race with Lilly

By Maggie Fick and Bhanvi Satija LONDON, Aug 3 - Novo Nordisk investors have found little cause for optimism during a bruising two-year period of profit warnings, leadership upheaval and a sliding share price as rival Eli Lilly streaked ahead. Now they may have reason for hope.
Trendline Trendline
Novo Nordisk Expands GLP-1 Drug Portfolio Amid Rising Market Competition

Novo Nordisk Expands GLP-1 Drug Portfolio Amid Rising Market Competition

Novo Nordisk Expands GLP-1 Drug Portfolio Amid Rising Market Competition
TheStreet TheStreet
Novo Nordisk shares in hot water after disappointing trial

Novo Nordisk shares in hot water after disappointing trial

Investors who had hopes that Novo Nordisk (NVO) could succeed outside of weight-loss drugs were disappointed on Friday, July 31. The Danish drugmaker said its experimental heart drug Ziltivekimab failed the main goal of a large late-stage trial, and the stock fell fast. Novo has spent 2026 trying ...